Skip to Main Content

Author Details

Carolina S Ilkow
Ottawa Hospital Research Institute
2006
51
16
PMIDPaper TitleJournal TitlePublished Year
36603053Identifying barriers and enablers to rigorous conduct and reporting of preclinical laboratory studies.PLoS Biol2023
37735876Optimal delivery of RNA interference by viral vectors for cancer therapy.Mol Ther2023
37822719A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection.Mol Ther Methods Clin Dev2023
37153626Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus.Front Immunol2023
37242495Engineering Rapalog-Inducible Genetic Switches Based on Split-T7 Polymerase to Regulate Oncolytic Virus-Driven Production of Tumour-Localized IL-12 for Anti-Cancer Immunotherapy.Pharmaceuticals (Basel)2023
37236967Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies.Nat Commun2023
37100284Inhibition of exchange proteins directly activated by cAMP as a strategy for broad-spectrum antiviral development.J Biol Chem2023
36969187Fatty acid transport protein inhibition sensitizes breast and ovarian cancers to oncolytic virus therapy <i>via</i> lipid modulation of the tumor microenvironment.Front Immunol2023
36587124Generation and Quantification of Cytotoxic Lymphocytes Following Oncolytic Virus Infection of Multi-cellular Tumor Spheroids.Methods Mol Biol2023
36713447CRISPR-mediated rapid arming of poxvirus vectors enables facile generation of the novel immunotherapeutic STINGPOX.Front Immunol2023
36674550Extracellular Vesicles and Viruses: Two Intertwined Entities.Int J Mol Sci2023
34687845Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection.Mol Ther2022
35393414Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy.Nat Commun2022
35526097Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen.Mol Ther2022
36405739Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.Front Immunol2022
35229029Intravesical immunotherapy with a GM-CSF armed oncolytic vesicular stomatitis virus improves outcome in bladder cancer.Mol Ther Oncolytics2022
34359574Oncolytic Virus Immunotherapy.Cancers (Basel)2021
37579261Luciferase-Based Biosensors in the Era of the COVID-19 Pandemic.ACS Nanosci Au2021
33706157SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition.Biosens Bioelectron2021
33668756Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction.Int J Mol Sci2021
33809836A High-Throughput NanoBiT-Based Serological Assay Detects SARS-CoV-2 Seroconversion.Nanomaterials (Basel)2021
33555379Personalized oncology and BRAF<sup>K601N</sup> melanoma: model development, drug discovery, and clinical correlation.J Cancer Res Clin Oncol2021
33578036Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry.Mol Ther2021
34459810Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter.J Vis Exp2021
34152313Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection.J Vis Exp2021
31486045Generating Primary Models of Human Cancer to Aid in the Development of Clinically Relevant Oncolytic Viruses.Methods Mol Biol2020
32958389Redirecting oncolytic viruses: Engineering opportunists to take control of the tumour microenvironment.Cytokine Growth Factor Rev2020
32872641Implications for SARS-CoV-2 Vaccine Design: Fusion of Spike Glycoprotein Transmembrane Domain to Receptor-Binding Domain Induces Trimerization.Membranes (Basel)2020
32722184Hippo Signaling Pathway as a Central Mediator of Receptors Tyrosine Kinases (RTKs) in Tumorigenesis.Cancers (Basel)2020
31276026Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies.Mol Ther Oncolytics2019
29367345Dimethyl fumarate potentiates oncolytic virotherapy through NF-κB inhibition.Sci Transl Med2018
29921327Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference.J Immunother Cancer2018
29724655Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.EBioMedicine2018
28810141A Viro-Immunotherapy Triple Play for the Treatment of Glioblastoma.Cancer Cell2017
27909702Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies.Mol Ther Oncolytics2016
25817275Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing.Nat Commun2015
26212250VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection.Cancer Cell2015
25894825Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity.Nat Med2015
25807289Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques.Mol Ther2015
24453963From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer.PLoS Pathog2014
24695102Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease.Mol Ther2014
24463573Smac mimetics and innate immune stimuli synergize to promote tumor death.Nat Biotechnol2014
24456140Phosphorylation and membrane association of the Rubella virus capsid protein is important for its anti-apoptotic function.Cell Microbiol2014
23393196Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.Cancer Res2013
22186794The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.Mol Ther2012
21379337The Rubella virus capsid is an anti-apoptotic protein that attenuates the pore-forming ability of Bax.PLoS Pathog2011
19846524The rubella virus capsid protein inhibits mitochondrial import.J Virol2010
20353299Rubella virus capsid protein: a small protein with big functions.Future Microbiol2010
18305028Rubella virus capsid protein interacts with poly(a)-binding protein and inhibits translation.J Virol2008
18258415Modulation of signaling pathways by RNA virus capsid proteins.Cell Signal2008
  • 1 - 50 of 51

Recommended Authors

Manasi P Jogalekar
University of California San Francisco
Career Start Year 2017
Number of shared co-authors 0
David Sachs
Icahn School of Medicine at Mount Sinai
Career Start Year 2013
Number of shared co-authors 1
Chengjin Ye
Texas Biomedical Research Institute
Career Start Year 2013
Number of shared co-authors 2
Andreas S Puschnik
Stanford University School of Medicine
Career Start Year 2013
Number of shared co-authors 0
Shashank Tripathi
Indian Institute of Science
Career Start Year 2011
Number of shared co-authors 0
Jennifer R Hamilton
University of California berkeley
Career Start Year 2011
Number of shared co-authors 0
Craig B Wilen
Yale School of Medicine
Career Start Year 2010
Number of shared co-authors 0
Gaurav Kumar
Gladstone Institutes
Career Start Year 2010
Number of shared co-authors 0
Siyuan Ding
Washington University School of Medicine
Career Start Year 2009
Number of shared co-authors 0
Thomas J Gardner
Icahn School of Medicine at Mount Sinai
Career Start Year 2009
Number of shared co-authors 0
Danyang Gong
David Geffen School of Medicine, University of California los angeles
Career Start Year 2009
Number of shared co-authors 0
Lisa Miorin
Icahn School of Medicine at Mount Sinai
Career Start Year 2008
Number of shared co-authors 2
Hans-Heinrich Hoffmann
The Rockefeller University
Career Start Year 2008
Number of shared co-authors 0
Mohsan Saeed
Boston University Chobanian and Avedisian School of Medicine
Career Start Year 2007
Number of shared co-authors 1
Stephanie A Montgomery
and Lineberger Comprehensive Cancer Center, University of North Carolina System
Career Start Year 2006
Number of shared co-authors 0
Nicholas S Heaton
Duke University School of Medicine
Career Start Year 2006
Number of shared co-authors 1
Alexandra Sch??fer
University of North Carolina at Chapel Hill
Career Start Year 2003
Number of shared co-authors 0
Aleksandra A Pandyra
Hematology and Clinical Immunology, Heinrich-Heine University Dusseldorf
Career Start Year 2003
Number of shared co-authors 1
Shirit Einav
Stanford University School of Medicine
Career Start Year 2002
Number of shared co-authors 0
Priya S Shah
University of California davis
Career Start Year 2002
Number of shared co-authors 0
Michael Denton
Vaccine and Gene Therapy Institute, Oregon Health and Science University
Career Start Year 2001
Number of shared co-authors 0
Luis Martinez-Sobrido
Texas Biomedical Research Institute
Career Start Year 2001
Number of shared co-authors 2
Renee C Ireton
Center for Innate Immunity and Immune Disease, University of Washington
Career Start Year 1997
Number of shared co-authors 0
Jan E Carette
Stanford University School of Medicine
Career Start Year 1996
Number of shared co-authors 0
J??rgen Haas
University of Edinburgh
Career Start Year 1996
Number of shared co-authors 0
Matthew B Frieman
Center for Pathogen Research, University of Maryland School of Medicine
Career Start Year 1993
Number of shared co-authors 1
Melanie Ott
Gladstone Institute of Virology
Career Start Year 1993
Number of shared co-authors 1
John W Barrett
University of Western Ontario
Career Start Year 1992
Number of shared co-authors 3
Ren Sun
University of California los angeles
Career Start Year 1992
Number of shared co-authors 0
Robert A Davey
Boston University
Career Start Year 1991
Number of shared co-authors 0

Collaborators

John C Bell
Ottawa Hospital Research Institute
Co-authored papers 32
Jean-Simon Diallo
Ottawa Hospital Research Institute, University of Ottawa
Co-authored papers 21
Taha Azad
Ottawa Hospital Research Institute
Co-authored papers 19
Mathieu J F Crupi
Cancer Research Institute, Queen's University
Co-authored papers 18
Ragunath Singaravelu
Ottawa Hospital Research Institute
Co-authored papers 14
Joanna Poutou
Ottawa Hospital Research Institute
Co-authored papers 12
Zaid Taha
Ottawa Hospital Research Institute, University of Ottawa
Co-authored papers 12
Abera Surendran
Ottawa Hospital Research Institute, The Ottawa Hospital
Co-authored papers 11
Julia Petryk
Ottawa Hospital Research Institute
Co-authored papers 11
Rebecca C Auer
The Ottawa Hospital Research Institute
Co-authored papers 9
Adrian Pelin
University of Ottawa
Co-authored papers 8
Xiao-Peng He
Ottawa Hospital Research Institute
Co-authored papers 8
Christiano Tanese de Souza
Ottawa Hospital Research Institute, The Ottawa Hospital
Co-authored papers 7
Brian A Keller
The Ottawa Hospital/University of Ottawa
Co-authored papers 6
Marie-??ve Wedge
Ottawa Hospital Research Institute
Co-authored papers 4
Larissa A Pikor
Ottawa Hospital Research Institute
Co-authored papers 4
Victoria A Jennings
Leeds Institute of Medical Research at St James's, University of Leeds
Co-authored papers 4
Sarwat T Khan
Ottawa Hospital Research Institute
Co-authored papers 3
Almohanad A Alkayyal
College of Applied Medical Sciences, University of Tabuk
Co-authored papers 3
Alan Melcher
The Institute of Cancer Research
Co-authored papers 2
Meaghan Boileau
Ottawa Hospital Research Institute
Co-authored papers 2
Avijit Chatterjee
The Ottawa Hospital
Co-authored papers 2
John D Lambris
Co-authored papers 2
Michele Geoffrion
University of Ottawa Heart Institute
Co-authored papers 1
Hayley E McKay
Ottawa Hospital Research Institute
Co-authored papers 1
Katey J Rayner
University of Ottawa
Co-authored papers 1
Jonathan Kimmelman
McGill University
Co-authored papers 1
Emily E F Brown
Ottawa Hospital Research Institute
Co-authored papers 1
Egon J Jacobus
Ottawa Hospital Research Institute
Co-authored papers 1
Paul C Boutros
University of California los angeles
Co-authored papers 1
Release 1.2